en.Wedoany.com Reported - New population-based study data from the Osaka International Cancer Institute in Japan shows that although the total number of cancer survivors has continued to increase over the past three decades, the number of secondary cancers related to radiation therapy has also risen simultaneously. The study focuses on treatment-related acute myeloid leukemia (tAML), an aggressive cancer of the blood and bone marrow.
Treatment-related acute myeloid leukemia typically occurs several years after receiving radiation therapy or chemotherapy for a primary cancer. Researchers point out that the cause of this phenomenon may be persistent DNA damage to cells caused during the treatment process. As radiation therapy and other methods have become increasingly popular in recent years, while improving the survival rates of primary cancers, they also carry the risk of inducing secondary cancers.
Lead author Dr. Kenji Kishimoto and his research team stated that as the cancer survivor population expands, the clinical relevance of treatment-related acute myeloid leukemia is significantly increasing. This study spans a 30-year observation period, aiming to determine the changing incidence of treatment-related acute myeloid leukemia in the Japanese societal context, as well as the impact of primary cancer evolution on secondary cancers.
The research findings suggest that while the medical community advances the popularization of advanced radiation therapy technologies, it must also place high importance on monitoring the long-term side effects of treatments. This discovery provides crucial evidence for evaluating the long-term safety of cancer treatment methods and emphasizes the urgency of seeking a balance between improving patient survival rates and controlling treatment-related cancer risks.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
